| Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma (NCT05260619) | Seoul National University Bundang Hospital | 2022-04-01 |
| Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma (NCT05209620) | Henan Cancer Hospital | 2021-12-21 |
| Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL (NCT05054426) | Peking Union Medical College Hospital | 2021-10-08 |
| Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma (NCT04938297) | Henan Cancer Hospital | 2021-05-26 |
| DALY II USA/ MB-CART2019.1 for DLBCL (NCT04792489) | Miltenyi Biomedicine GmbH | 2021-05-25 |
| A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas (NCT04548648) | UNC Lineberger Comprehensive Cancer Center | 2020-10-15 |
| A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients (NCT04516655) | Fudan University | 2020-09-01 |
| CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520) | Medical College of Wisconsin | 2020-05-18 |
| Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies (NCT05011045) | M.D. Anderson Cancer Center | 2020-01-09 |
| Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) (NCT03964090) | National Cancer Institute (NCI) | 2019-06-27 |
| LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma (NCT03684980) | Memorial Sloan Kettering Cancer Center | 2018-11-14 |
| Long-term Follow-up Study of Patients Receiving CAR-T Cells (NCT03375619) | Medical College of Wisconsin | 2017-12-01 |
| Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity (NCT03342586) | Memorial Sloan Kettering Cancer Center | 2017-11-07 |
| Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom (NCT02952508) | Cellectar Biosciences, Inc. | 2017-07-26 |
| Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma (NCT02623010) | Rabin Medical Center | 2016-10-01 |
| Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma (NCT02652715) | Mayo Clinic | 2016-01-19 |
| Molecular Prognosis of Lymphomas of the Central Nervous System (ALYCE-molecular) (NCT03859544) | Hospices Civils de Lyon | 2016-01-01 |
| Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT02420795) | M.D. Anderson Cancer Center | 2015-11-03 |
| High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Central Nervous System Lymphoma (NCT06625359) | Seoul National University Hospital | 2015-06-01 |
| MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway (NCT03962127) | Norwegian University of Science and Technology | 2015-05-01 |
| Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy (NCT03690895) | Fondation Ophtalmologique Adolphe de Rothschild | 2015-03-15 |
| Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma (NCT01722305) | Mayo Clinic | 2013-04-08 |
| Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (NCT01011920) | International Extranodal Lymphoma Study Group (IELSG) | 2009-11-01 |
| Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed) (NCT00916630) | Massachusetts General Hospital | 2009-01-01 |
| Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (NCT01458730) | University of Aarhus | 2007-05-01 |
| A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma (NCT00221325) | University of California, San Francisco | 2007-04-01 |
| Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma (NCT00293475) | OHSU Knight Cancer Institute | 2005-10-14 |
| Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases (NCT00103038) | OHSU Knight Cancer Institute | 2004-06-04 |
| Study of Tissue Samples From Patients With Glioma or Other Brain Tumors (NCT00967200) | University Hospital, Montpellier | 2003-11-01 |
| Cognitive Functioning and Quality of Life in CNS Lymphoma (NCT00581737) | Memorial Sloan Kettering Cancer Center | 2000-07-01 |
| Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) (NCT00153530) | Charite University, Berlin, Germany | 2000-05-01 |